Finch Therapeutics Group Inc. (FNCH) PT Lowered to $17 at Jefferies

Jefferies analyst Roger Song lowered the price target on Finch Therapeutics Group Inc. (NASDAQ: FNCH) to $17.00 (from $29.00) while maintaining a Buy rating.

The analyst commented, "Co was unable to immediately resolve the clinical hold - a variety of issues require additional alignment with the FDA (testing algorithm, protocol, manufacturing changes, etc). While all issues should be addressable, at least a quarter delay is now expected. rCDI and autism programs are on hold and HBV is now shelved. Given the uncertainty, we delay the launch and reduce program PoS to 50% - PT to $17 but remain Buy."

You May Also Be Interested In

• Aebi Schmidt Holding AG (AEBI) PT Raised to $17 at DA Davidson Following Q2 Results
• Target (TGT) PT Raised to $170 at DA Davidson Ahead of Q2 Earnings
• Quanterix Corp. (QTRX) PT Lowered to $3 at Canaccord